The Vascular Disrupting Agents Market Size is valued at 105.42 Million in 2022 and is predicted to reach 2298.64 Million by the year 2031 at a 41.4 % CAGR during the forecast period for 2023-2031.
Vascular disrupting agents (VDAs) are a novel family of medications that target the existing tumour vasculature and cause tumour necrosis. As the world's population has aged, so has the global burden of cancer morbidity and mortality. Cancer is the primary or second leading cause of death among persons under the age of 70 in 112 of 183 countries, according to World Health Organization estimates in 2019. Vascular disrupting agents are the medications utilized in tumour vascular disrupting treatment (VDAs). VDAs can specifically target tumour vasculature via several mechanisms, inhibiting blood flow within tumours and causing widespread secondary necrosis while leaving normal tissues largely unscathed. These agents are used to treat various cancer types such as thyroid cancer, liver cancer, ovarian cancer, and colorectal cancer.
Factors driving the growth of the vascular disrupting agents market include the high prevalence rate of cancer, rising geriatric population, increasing demand for advanced cancer therapy options, growing public awareness about novel therapy treatments, increasing government expenditure for cancer therapy research and development, expiry of patents for various drugs, and the changing lifestyle standards. Furthermore, pharmaceutical companies are investing more in cancer research due to the growing list of risk factors and cancer-causing agents of existing anticancer therapies, thereby creating growth opportunities for the vascular disrupting agents market. However, the high cost of target therapies and the lack of availability of safety data may restrict the market growth in the future.
Market Segmentation
The vascular disrupting agents market is classified based on indications, therapeutic area, molecules, therapy, route of administration, product, and region. Based on the indications, the market comprises chemotherapy-induced neutropenia, glioblastoma, liver cancer, mesothelioma, non-small cell lung cancer, prostate cancer, ovarian cancer, renal pelvis, and ureter cancer. The market is segmented into hematological malignancies and solid tumors by therapeutic area. By molecules, the market is divided into tubulin binding agents, flavonoids, and ligand-directed agents. The Tubulin Binding Agents and Flavonoids segments are anticipated to expand over the forecast period as the small molecules are majorly used in the pipeline. In terms of therapy, the market is bifurcated into mono and combination. by route of administration, the market is classified into oral and intravenous. The product segment is categorized into Bavituximab, Icaritin, NGR-TNF, Padeliporfin, Plinabulin, VB-111, and others. Regionally, the market is categorized across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America will likely hold the highest share of this market in the next few years due to the well-established healthcare infrastructures, growing elderly population, and rising patient awareness regarding the benefits of new targeted therapies.
Competitive Landscape
Some major key players in the Vascular Disrupting Agents Market:
- AGC Biologics
- Avid Bioservices
- Bionomics
- Beijing Shenogen Biomedical
- Mateon Therapeutics
- Myrexis
- VBL Therapeutics
- Steba biotech
- BeyondSpring Pharmaceuticals
- Immune Pharmaceuticals
- Nereus Pharmaceuticals
- Madrigal Pharmaceuticals, Inc.
- Celgene Corporation
- Bionomics Ltd.
- Lees Pharmaceutical Holdings.
- Other Prominent Players
Vascular Disrupting Agents Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 105.42 Million |
|
Revenue forecast in 2031 |
USD 2298.64 Million |
|
Growth rate CAGR |
CAGR of 41.4 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Indication, By Therapeutic Area, By Product, By Molecule, By Therapy, By Route of Administration |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
AGC Biologics (Denmark), Avid Bioservices (US), Bionomics (Australia), Beijing Shenogen Biomedical (China), Mateon Therapeutics (US), Myrexis (US), VBL Therapeutics (Israel), Steba biotech (US), BeyondSpring Pharmaceuticals (US), Immune Pharmaceuticals (US), Nereus Pharmaceuticals (US), Madrigal Pharmaceuticals, Inc. (US), Celgene Corporation (US), Bionomics Ltd. (Australia), Lees Pharmaceutical Holdings. (Hong Kong), and others. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
